At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
AZD9668 +1 moredrug
Likely dose
AZD9668 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients With Bronchiectasis
In Brief
A Phase 2 clinical trial evaluating AZD9668 and Placebo for Bronchiectasis. Completed, enrolled 38 participants across 9 sites in 2 countries.
Detailed Summary
The purpose of this study is to investigate if treatment with AZD9668 for 28 days is effective in treating Bronchiectasis (Brx) and if so how it compares to placebo (a substance which does not have any action).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBronchiectasis
CountriesCanada, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedOct 2008
Primary CompletionApr 2009
TodayJul 2026
First PostedOct 8, 2008
Enrollment StartSep 1, 2008
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.7 years ago
Interventions
AZD9668drug
2 x 30 mg, oral tablet, twice daily for 28 days
Placebodrug
2 x Matched placebo, oral tablet, twice daily for 28 days